Nicotine De-Addiction Products Market Size, Share & Industry Analysis, By Product Type (Nicotine Replacement Therapy products, Drug Therapy Products, Nicotine Sublingual Tablets, Inhalers, Others), By Distribution Channel (Hypermarkets & Supermarkets, Pharmacy Stores, Online Stores, Duty-Free Shops, Others) And Regional Forecast, 2024-2032

Nicotine de-addiction products are essentially used by people to quit their drug addiction habits. Companies commonly use the varenicline medication method in their nicotine de-addiction related drug therapy products to help individuals change their nicotine intake habit. Sugar-free nicotine de-addiction products of different flavors such as mint, chocolate, and others are popularly consumed by diabetic patients across the globe. Introduction of the nicotine replacement therapy is likely to add impetus to the demand for such kind of products.

Nowadays, people are increasingly suffering from lung cancer, asthma, and others due to the over intake of tobacco products. Therefore, rising awareness regarding the health hazards of such kind of products resulted in the greater consumer demand for tobacco de-addiction related products across the globe. According to the data presented by the American Cancer Society, in 2020, the number of newer lung cancer-related cases reached 228,820 in America.

Rising awareness regarding the availability of the different kinds of tobacco replacement related products such as de-addiction chewing gums, inhalers, tablets, and others is expected to drive the market growth. Additionally, shifting consumer preferences towards the usage of herbal medicinal products is expected to drive the demand for nicotine replacement tablets & powders made up of extracts of plants such as Camellia sinensis, cloves, lobelia, and others. The emergence of the locally available smoking de-addiction related services is expected to support the consumption rate of such kind of products.

Moreover, positive governmental support regarding the spreading of awareness related to the health hazards of regularly consuming tobacco products by people across many countries is expected to fuel market growth. For instance, in March 2019, the Government of India (GOI) introduced Nirmal, a nicotine replacement gum, under its Pradhan Mantri Bhartiya Janaaushadhi Pariyojana (PMBJP) to fight against tobacco addiction in India.

However, incidences of health hazards, including blood cell damages, oral infection, and others, due to the over-intake of tobacco de-addiction related products are anticipated to restrain the market growth. Additionally, large competition from the local industry players is expected to limit the market growth. 

Key Players Covered:

The key players involved in the global nicotine de-addiction products market are GlaxoSmithKline Plc., Pfizer Inc., Perrigo Company, Honeyrose Products Ltd., Novartis International AG, Johnson & Johnson, Revolymer PLC, Cipla Ltd., McNeil AB, Rusan Healthcare Private Ltd., and others.

The global nicotine de-addiction products market is segmented based on product type, distribution channel, and geography.

Based on product type, the market is segmented into nicotine replacement therapy products, drug therapy products, nicotine sublingual tablets, inhalers, and others. Nicotine replacement therapy includes various products such as lozenges, gums, sprays, and transdermal patches. The nicotine replacement therapy products segment is expected to hold a major share of the market owing to the wide availability variety of cost-effective nicotine replacement therapy-related products across the globe. Additionally, the higher effectiveness of such products over other types results in large revenues from this segment.

By distribution channel, the global market is segmented into hypermarkets & supermarkets, pharmacy stores, online stores, duty-free shops, and others. The largest share of the hypermarkets & supermarkets segment is attributed to the availability of the wide variety of smoking de-addiction products at these stores. Additionally, consumers prefer to buy grocery items from these stores to get discounts on the select product purchases made by them at these stores. This results in the large consumption of nicotine de-addiction related products from these stores.

Regional Analysis:

By geography, the global nicotine de-addiction products market is segmented into North America, Europe, Asia Pacific, South America, and Middle East & Africa.

The largest share of the Asia Pacific region is attributed to the presence of a large number of tobacco users in the countries such as China and India which thereby, results in the large usage of tobacco de-addiction-related products among these users. According to the data presented by the Tobacco-Free Kids Organisation, as of October 2020, 26.6% of the Chinese population smokes on a daily basis. Additionally, growing awareness regarding the health hazards of tobacco-related products among the population is further driving the market growth in the region.

North America region is expected to grow at a considerable rate owing to the shifting consumer preferences towards the usage of the plant-based, nicotine de-addiction related products in the countries such as the United States and Mexico. This is likely to drive the demand for the different kinds of nicotine de-addiction-related products made up of extracts of plants such as camellia sinensis, cloves, lobelia, and others in the region.

Additionally, the large demand for e-cigarettes among the U.S. population is expected to result in the large usage of the addiction replacement related e-inhalers among them for quitting smoking. This helps in supporting the market growth in the region. According to the data presented by the Federation of American Scientists, in 2018, 8.1 million U.S. adult population preferred to use e-cigarettes regularly.

Segmentation

Key Industry Developments:

• In July 2020, Dr.  Reddy’s Laboratories, an Indian pharmaceutical company launched over-the-counter nicotine polacrilex lozenges in the American market.


• In May 2019, GlaxoSmithKline Plc., a global pharmaceutical giant, launched a new nicotine lozenge under its brand Nicorette to help people to quit smoking.